Commentary

Dec 7, 2010

If you are like me, you probably received a lot of phone calls from patients and prescribers when the news hit about the potential interaction between clopidogrel and proton pump inhibitors (PPIs).  In January 2009, the Food and Drug Administration (FDA) published data from an ongoing safety review of clopidogrel effectiveness, which resulted in a November 2009 Public Health Advisory that recommended avoiding of the combination of clopidogrel and any PPIs...

Comments: 3      Views: 11,150


Nov 4, 2010

Clinicians and patients alike have been anxiously waiting for an oral alternative to warfarin. That wait appears to be finally over. On October 19, 2010 dabigatran (Pradaxa®) was approved by the FDA and became the first oral direct thrombin inhibitor available in the United States. Unlike its predecessor ximelagatran, dabigatran doesn’t seem to cause liver toxicity. And unlike warfarin, dabigatran is administered as a fixed dose and requires no ongoing...

Comments: 8      Views: 23,474


Oct 18, 2010

Non-alcoholic fatty liver disease (NAFLD) is a condition characterized by fat deposition in the hepatocytes of patients with minimal or no alcohol intake.  NAFLD has emerged as the leading cause of chronic liver disease in the Western world, with an estimated prevalence of 20-30% in the general population.1  Patients with NAFLD may present along spectrum of histological findings, ranging from simple hepatic steatosis (fat accumulation without inflammation or fibrosis) to nonalcoholic...

Comments: 0      Views: 4,592


Mar 30, 2010

UPDATE:  See related story regarding editorial and open letter to NCEP ATP IV

I’ve long believed that statin therapy should be guided by a clinical risk assessment – not LDL cholesterol goals. None of the landmark clinical trials demonstrating the benefits of statin therapy have titrated the dose to an LDL goal. None. Participants were eligible for the studies based on clinical...

Comments: 2      Views: 10,741


Pages